<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>OB/GYN Study Guide | M & M Consulting</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <meta name="description" content="In-depth study guide for Obstetrics & Gynecology topics on the PANCE exam." />
  <meta name="keywords" content="PANCE, OB/GYN, obstetrics, gynecology, exam preparation, study guide" />
  <meta name="author" content="M & M Consulting" />

  <link rel="stylesheet" href="style.css" />
</head>
<body>
  <header>
    <nav class="top-nav" role="navigation" aria-label="Main navigation">
      <h2 class="visually-hidden">Main Navigation</h2>
      <div class="nav-brand">
        <a href="home.html" aria-label="Go to home page">M & M Consulting</a>
      </div>
      <button class="nav-toggle" id="nav-toggle" aria-label="Toggle navigation menu" aria-expanded="false">
        &#9776;
      </button>
      <ul class="nav-links" id="nav-links">
        <li><a href="home.html">Home</a></li>
        <li><a href="index.html">Quizzes</a></li>
        <li><a href="studyguides.html">Study Guides</a></li>
        <li><a href="summary.html">OB/GYN Quiz Summary</a></li>
      </ul>
    </nav>
  </header>

  <main class="page-container study-guide-landing" role="main">
    <h1>Obstetrics &amp; Gynecology Study Guide</h1>
    <p class="intro-text">
      Welcome to the comprehensive OB/GYN study guide. This resource integrates the most essential topics for PANCE preparation, from normal pregnancy and reproductive health to critical obstetric and gynecologic complications. Use this guide alongside our quizzes for optimal learning.
    </p>

    <!-- Table of Contents -->
    <section>
      <h2>Table of Contents</h2>
      <ol>
        <li>Normal Pregnancy &amp; Prenatal Care
          <ul>
            <li>Gestational Age &amp; Dating</li>
            <li>Maternal Physiologic Changes</li>
            <li>Prenatal Visits &amp; Initial Labs</li>
            <li>Screening Tests &amp; Genetic Screening</li>
            <li>Nutritional &amp; Lifestyle Guidance</li>
            <li>Fetal Well-Being &amp; Surveillance</li>
          </ul>
        </li>
        <li>Complications of Pregnancy
          <ul>
            <li>Gestational Diabetes Mellitus (GDM)</li>
            <li>Hypertensive Disorders of Pregnancy</li>
            <li>Preterm Labor &amp; Premature Rupture of Membranes (PROM/PPROM)</li>
            <li>Placental Abnormalities</li>
            <li>Hyperemesis Gravidarum</li>
            <li>Multiple Gestation</li>
            <li>Intrahepatic Cholestasis of Pregnancy</li>
            <li>Other Notable Obstetric Complications</li>
          </ul>
        </li>
        <li>Labor &amp; Delivery
          <ul>
            <li>Stages of Labor</li>
            <li>Labor Analgesia &amp; Pain Management</li>
            <li>Normal vs. Abnormal Labor Progression</li>
            <li>Operative Delivery (Vacuum/Forceps, Cesarean Section)</li>
            <li>Fetal Monitoring &amp; Interpretation</li>
          </ul>
        </li>
        <li>Postpartum Care &amp; Complications
          <ul>
            <li>Immediate Postpartum Period</li>
            <li>Postpartum Hemorrhage (PPH)</li>
            <li>Postpartum Infections (Endometritis, Mastitis)</li>
            <li>Postpartum Mood Disorders</li>
            <li>Lactation &amp; Breastfeeding</li>
          </ul>
        </li>
        <li>Contraception &amp; Family Planning
          <ul>
            <li>Hormonal Methods (Combined, Progestin-only, Depot, Implant)</li>
            <li>Intrauterine Devices (IUDs)</li>
            <li>Barrier Methods &amp; Sterilization</li>
            <li>Emergency Contraception</li>
          </ul>
        </li>
        <li>Gynecology: General Topics
          <ul>
            <li>Menstrual Disorders</li>
            <li>Menopause &amp; Perimenopause</li>
            <li>Pelvic Organ Prolapse</li>
            <li>Urinary Incontinence</li>
            <li>Pelvic Pain &amp; Dysmenorrhea</li>
            <li>Endometriosis</li>
            <li>Uterine Leiomyomas (Fibroids)</li>
            <li>Adenomyosis</li>
          </ul>
        </li>
        <li>Gynecologic Oncology
          <ul>
            <li>Cervical Cancer</li>
            <li>Endometrial (Uterine) Cancer</li>
            <li>Ovarian Cancer</li>
            <li>Vulvar &amp; Vaginal Cancers</li>
            <li>Gestational Trophoblastic Disease (GTD)</li>
          </ul>
        </li>
        <li>Breast Disorders
          <ul>
            <li>Benign Breast Conditions</li>
            <li>Malignant Breast Disease</li>
            <li>Screening &amp; Imaging Modalities</li>
          </ul>
        </li>
        <li>Reproductive Endocrinology &amp; Infertility
          <ul>
            <li>Definitions &amp; Workup</li>
            <li>Common Causes (PCOS, Ovulatory Disorders, Tubal Factors, Male Factors)</li>
            <li>Treatments (Ovulation Induction, ART/IVF)</li>
          </ul>
        </li>
        <li>Sexually Transmitted Infections (STIs) &amp; Other Gynecologic Infections
          <ul>
            <li>Common STIs (Chlamydia, Gonorrhea, Trichomoniasis, Syphilis, HSV, HPV)</li>
            <li>Vaginitis &amp; Vaginosis (Candida, BV)</li>
            <li>PID (Pelvic Inflammatory Disease)</li>
            <li>Screening in Pregnancy</li>
          </ul>
        </li>
        <li>Ectopic Pregnancy
          <ul>
            <li>Risk Factors, Clinical Presentation, Diagnosis</li>
            <li>Management (Medical vs. Surgical)</li>
          </ul>
        </li>
      </ol>
    </section>

    <!-- 1. Normal Pregnancy & Prenatal Care -->
    <section>
      <h2>1. Normal Pregnancy &amp; Prenatal Care</h2>

      <h3>1.1. Gestational Age &amp; Dating</h3>
      <ul>
        <li><strong>Naegele’s Rule</strong>:
          <ul>
            <li>EDD (Estimated Due Date) = (First day of LMP) + 7 days – 3 months + 1 year.</li>
            <li>Assumes a 28-day cycle with ovulation on day 14.</li>
          </ul>
        </li>
        <li><strong>Ultrasound Dating</strong>:
          <ul>
            <li>First-Trimester Crown-Rump Length (CRL) is the most accurate (± 5–7 days).</li>
            <li>Second-Trimester Ultrasound accuracy: ± 7–14 days.</li>
            <li>Third-Trimester Ultrasound accuracy: ± 14–21 days.</li>
            <li>Importance: Accurate dating reduces iatrogenic inductions, prevents unnecessary interventions for “suspected post-dates,” and improves scheduling of prenatal tests.</li>
          </ul>
        </li>
      </ul>

      <h3>1.2. Maternal Physiologic Changes</h3>
      <ul>
        <li><strong>Cardiovascular</strong>:
          <ul>
            <li>↑ Blood volume (by ~50%), ↑ Cardiac output (by ~30–50%), ↓ SVR (systemic vascular resistance).</li>
            <li>Resultant physiologic anemia (lower hematocrit due to plasma volume expansion).</li>
          </ul>
        </li>
        <li><strong>Respiratory</strong>:
          <ul>
            <li>↑ Tidal volume, mild respiratory alkalosis, ↑ minute ventilation.</li>
            <li>Diaphragm elevated by enlarging uterus → decreased functional residual capacity.</li>
          </ul>
        </li>
        <li><strong>Renal</strong>:
          <ul>
            <li>↑ GFR, ↓ BUN/Cr, mild glycosuria can be normal but must differentiate from GDM.</li>
          </ul>
        </li>
        <li><strong>GI</strong>:
          <ul>
            <li>Slowed gastric emptying and bowel transit (↑ risk of constipation, reflux).</li>
          </ul>
        </li>
        <li><strong>Coagulation</strong>:
          <ul>
            <li>Hypercoagulable state (↑ fibrinogen, factors VII, VIII, X), protective for hemorrhage but ↑ VTE risk.</li>
          </ul>
        </li>
      </ul>

      <h3>1.3. Prenatal Visits &amp; Initial Labs</h3>
      <ul>
        <li><strong>Frequency</strong>:
          <ul>
            <li>Every 4 weeks until 28 weeks.</li>
            <li>Every 2 weeks from 28–36 weeks.</li>
            <li>Weekly from 36 weeks until delivery.</li>
          </ul>
        </li>
        <li><strong>Initial Labs</strong>:
          <ul>
            <li>CBC (check for anemia, baseline platelet count).</li>
            <li>Blood type and Rh (prevent isoimmunization with Rho(D) immune globulin if Rh negative).</li>
            <li>Antibody screen (irregular antibodies).</li>
            <li>Infection screening: HIV, Syphilis (RPR/VDRL), Hepatitis B surface antigen (HBsAg).</li>
            <li>Rubella &amp; Varicella titers to confirm immunity.</li>
            <li>Urine culture or urine dip to screen for asymptomatic bacteriuria.</li>
          </ul>
        </li>
        <li><strong>Ongoing Visits</strong>:
          <ul>
            <li>Fundal height measurement (beginning ~20 weeks; height in cm ≈ gestational age).</li>
            <li>Fetal heart rate (110–160 bpm is normal).</li>
            <li>Maternal vital signs (especially BP).</li>
            <li>Weight and urine dip (protein, glucose).</li>
          </ul>
        </li>
      </ul>

      <h3>1.4. Screening Tests &amp; Genetic Screening</h3>
      <ul>
        <li><strong>Optional/Recommended Genetic Tests</strong> (varies by risk factors, patient preference):
          <ul>
            <li>Cystic Fibrosis (CF) carrier screening.</li>
            <li>Hemoglobinopathies (e.g., sickle cell, thalassemias) based on ethnicity.</li>
            <li>First-Trimester Screen (PAPP-A, β-hCG, nuchal translucency ultrasound).</li>
            <li>Cell-free fetal DNA testing (cfDNA) for aneuploidies (trisomies 21, 18, 13).</li>
            <li>Quad Screen in second trimester (AFP, β-hCG, Estriol, Inhibin A).</li>
          </ul>
        </li>
        <li><strong>Timing</strong>:
          <ul>
            <li>10–13 weeks: Nuchal translucency + PAPP-A + hCG (or cell-free DNA).</li>
            <li>15–20 weeks: Quad screen ± further imaging.</li>
          </ul>
        </li>
      </ul>

      <h3>1.5. Nutritional &amp; Lifestyle Guidance</h3>
      <ul>
        <li><strong>Folic Acid</strong>: 0.4–0.8 mg/day to prevent neural tube defects; 4 mg/day if prior child with NTD.</li>
        <li><strong>Iron</strong>: Supplement if anemic; prenatal vitamins typically contain ~27–30 mg iron.</li>
        <li><strong>Calcium</strong>: 1000–1300 mg/day to support fetal bone growth.</li>
        <li><strong>Vitamin D</strong>: ~600–800 IU/day; consider higher in deficiency.</li>
        <li><strong>Exercise</strong>: Moderate intensity, avoid contact/high-impact sports; continue pre-pregnancy routines if safe.</li>
        <li><strong>Immunizations</strong>:
          <ul>
            <li>Influenza (inactivated) annually.</li>
            <li>Tdap between 27–36 weeks each pregnancy.</li>
            <li>COVID-19 vaccines as recommended by CDC/ACOG.</li>
          </ul>
        </li>
        <li><strong>Avoid Teratogens</strong>:
          <ul>
            <li>No alcohol or illicit drugs; minimize caffeine (&lt;200 mg/day).</li>
            <li>No smoking (↑ risks of IUGR, abruption, preterm birth).</li>
            <li>Medications: Avoid ACE inhibitors, isotretinoin, warfarin, etc.</li>
          </ul>
        </li>
      </ul>

      <h3>1.6. Fetal Well-Being &amp; Surveillance</h3>
      <ul>
        <li>Fetal Movement Counts (“kick counts”).</li>
        <li><strong>Non-Stress Test (NST)</strong>:
          <ul>
            <li>Reactive (reassuring) = ≥2 accelerations of FHR (15 bpm above baseline for 15 seconds) in 20 min.</li>
            <li>Non-reactive → further testing (BPP or CST).</li>
          </ul>
        </li>
        <li><strong>Biophysical Profile (BPP)</strong>:
          <ul>
            <li>NST + ultrasound parameters (fetal breathing movements, gross body movements, fetal tone, amniotic fluid index).</li>
            <li>Score out of 10; ≤4 is worrisome.</li>
          </ul>
        </li>
        <li><strong>Doppler Velocimetry</strong> for high-risk pregnancies (e.g., IUGR, preeclampsia).</li>
        <li><strong>Contraction Stress Test (CST)</strong>: Observes FHR changes with uterine contractions.</li>
      </ul>
    </section>

    <!-- 2. Complications of Pregnancy -->
    <section>
      <h2>2. Complications of Pregnancy</h2>

      <h3>2.1. Gestational Diabetes Mellitus (GDM)</h3>
      <ul>
        <li><strong>Screening</strong>:
          <ul>
            <li>At 24–28 weeks with 1-hour 50 g glucose challenge test (GCT).</li>
            <li>If ≥140 mg/dL (some use 130 or 135 mg/dL cutoff), proceed to 3-hour OGTT.</li>
            <li>3-hour OGTT (100 g) diagnostic criteria (Carpenter &amp; Coustan):
              <ul>
                <li>Fasting ≥ 95 mg/dL</li>
                <li>1-hour ≥ 180 mg/dL</li>
                <li>2-hour ≥ 155 mg/dL</li>
                <li>3-hour ≥ 140 mg/dL</li>
                <li>(2 or more abnormal values = GDM)</li>
              </ul>
            </li>
          </ul>
        </li>
        <li><strong>Management</strong>:
          <ul>
            <li>Dietary modifications, glucose monitoring (fasting + postprandial).</li>
            <li>Insulin is first-line pharmacotherapy if glycemic targets not met with diet.</li>
            <li>Oral agents (e.g., metformin, glyburide) used, though insulin often preferred.</li>
          </ul>
        </li>
        <li><strong>Risks</strong>:
          <ul>
            <li>Fetal macrosomia, neonatal hypoglycemia, birth trauma (shoulder dystocia).</li>
            <li>Long-term risk of T2DM in mother and child.</li>
          </ul>
        </li>
      </ul>

      <h3>2.2. Hypertensive Disorders of Pregnancy</h3>
      <ul>
        <li><strong>Chronic Hypertension</strong>: BP ≥140/90 before pregnancy or &lt;20 weeks gestation.</li>
        <li><strong>Gestational Hypertension</strong>: New onset ≥140/90 after 20 weeks without proteinuria or other systemic findings.</li>
        <li><strong>Preeclampsia</strong>:
          <ul>
            <li>BP ≥140/90 after 20 weeks + proteinuria (≥300 mg/24 hr) or end-organ dysfunction (thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, cerebral/visual disturbances).</li>
            <li>With Severe Features: BP ≥160/110, severe headaches, RUQ/epigastric pain, elevated liver enzymes, etc.</li>
          </ul>
        </li>
        <li><strong>Eclampsia</strong>: Preeclampsia + seizures (generalized tonic-clonic).</li>
        <li><strong>HELLP Syndrome</strong>: Hemolysis, Elevated Liver enzymes, Low Platelets.</li>
        <li><strong>Management</strong>:
          <ul>
            <li>Mild preeclampsia near term: Delivery at 37 weeks.</li>
            <li>Severe preeclampsia: Control BP (IV labetalol, hydralazine, or PO nifedipine), Magnesium sulfate for seizure prophylaxis, expedite delivery (≥34 weeks).</li>
            <li>Eclampsia: IV magnesium sulfate + antihypertensives, immediate delivery once stable.</li>
            <li>Long-Term: Women with preeclampsia have ↑ risk of cardiovascular disease later in life.</li>
          </ul>
        </li>
      </ul>

      <h3>2.3. Preterm Labor &amp; Premature Rupture of Membranes (PROM/PPROM)</h3>
      <ul>
        <li><strong>Definitions</strong>:
          <ul>
            <li>Preterm Labor: Regular uterine contractions with cervical change before 37 weeks.</li>
            <li>PROM: Rupture of membranes before labor onset at term (≥37 weeks).</li>
            <li>PPROM: Rupture of membranes before labor onset and before 37 weeks.</li>
          </ul>
        </li>
        <li><strong>Diagnosis</strong>: Nitrazine test (pH), fern test, speculum exam for pooling.</li>
        <li><strong>Management</strong>:
          <ul>
            <li>Tocolytics (nifedipine, indomethacin, terbutaline, magnesium sulfate) to delay labor if no contraindications.</li>
            <li>Corticosteroids (betamethasone or dexamethasone) if &lt;34 weeks to enhance fetal lung maturity.</li>
            <li>Magnesium sulfate for fetal neuroprotection &lt;32 weeks (decreases risk of cerebral palsy).</li>
            <li>Group B Streptococcus (GBS) prophylaxis if indicated.</li>
          </ul>
        </li>
      </ul>

      <h3>2.4. Placental Abnormalities</h3>
      <ul>
        <li><strong>Placenta Previa</strong>:
          <ul>
            <li>Placental tissue covering or near the internal cervical os.</li>
            <li>Painless bright red vaginal bleeding in the 3rd trimester.</li>
            <li>Diagnosis by ultrasound; avoid digital cervical exam if suspected.</li>
            <li>Often requires cesarean delivery if complete or marginal covering.</li>
          </ul>
        </li>
        <li><strong>Placental Abruption</strong>:
          <ul>
            <li>Premature separation of placenta from uterine wall.</li>
            <li>Painful vaginal bleeding, uterine tenderness, hypertonic uterus, possible fetal distress.</li>
            <li>Risk factors: Hypertension, trauma, cocaine use, smoking, history of abruption.</li>
          </ul>
        </li>
        <li><strong>Placenta Accreta Spectrum</strong>:
          <ul>
            <li>Accreta (superficial attachment), Increta (invasion into myometrium), Percreta (through serosa).</li>
            <li>Risk with prior C-section + placenta previa.</li>
            <li>Can cause massive postpartum hemorrhage; may require hysterectomy.</li>
          </ul>
        </li>
      </ul>

      <h3>2.5. Hyperemesis Gravidarum</h3>
      <ul>
        <li>Severe, persistent nausea/vomiting, weight loss &gt;5% of pre-pregnancy weight, dehydration, electrolyte imbalances, ketonuria.</li>
        <li>Differential: Rule out molar pregnancy, thyroid disorders, GI etiologies.</li>
        <li>Management:
          <ul>
            <li>IV fluids, thiamine supplementation (to prevent Wernicke’s encephalopathy).</li>
            <li>Antiemetics: Pyridoxine (vit B6) ± doxylamine, ondansetron, promethazine, metoclopramide.</li>
            <li>Correct electrolyte imbalances (hypokalemia, metabolic alkalosis).</li>
          </ul>
        </li>
      </ul>

      <h3>2.6. Multiple Gestation</h3>
      <ul>
        <li><strong>Types</strong>:
          <ul>
            <li>Dizygotic (fraternal): Two separate ova, two placentas, two sacs.</li>
            <li>Monozygotic (identical): One fertilized ovum splits; various chorionic/amniotic configurations depending on timing of split.</li>
          </ul>
        </li>
        <li><strong>Risks</strong>:
          <ul>
            <li>Preterm labor, low birth weight, gestational hypertension, preeclampsia, GDM.</li>
            <li>Monochorionic twins risk Twin-Twin Transfusion Syndrome (TTTS).</li>
          </ul>
        </li>
        <li><strong>Management</strong>:
          <ul>
            <li>More frequent ultrasounds to monitor fetal growth.</li>
            <li>Surveillance for TTTS in monochorionic gestations.</li>
          </ul>
        </li>
      </ul>

      <h3>2.7. Intrahepatic Cholestasis of Pregnancy</h3>
      <ul>
        <li>Generalized pruritus (often worse at night, on palms/soles), elevated bile acids.</li>
        <li>Risks: Fetal distress, preterm delivery, meconium passage, stillbirth.</li>
        <li>Management:
          <ul>
            <li>Ursodeoxycholic acid (UDCA) to reduce bile acids and itching.</li>
            <li>Close fetal monitoring, consider delivery at 36–37 weeks if severe.</li>
          </ul>
        </li>
      </ul>

      <h3>2.8. Other Notable Obstetric Complications</h3>
      <ul>
        <li><strong>Rh Isoimmunization</strong>:
          <ul>
            <li>Occurs if Rh– mother is exposed to Rh+ fetal blood → maternal anti-D IgG → hemolysis in subsequent pregnancies.</li>
            <li>Rho(D) immune globulin (RhoGAM) at 28 weeks and within 72 hours postpartum if baby is Rh+.</li>
          </ul>
        </li>
        <li><strong>ABO Incompatibility</strong>: Usually milder than Rh disease (mother is blood group O, baby is A/B).</li>
        <li><strong>Amniotic Fluid Abnormalities</strong>:
          <ul>
            <li>Polyhydramnios: &gt;24 cm AFI; associated with GDM, fetal anomalies.</li>
            <li>Oligohydramnios: &lt;5 cm AFI; associated with rupture of membranes, placental insufficiency, fetal renal anomalies.</li>
          </ul>
        </li>
      </ul>
    </section>

    <!-- 3. Labor & Delivery -->
    <section>
      <h2>3. Labor &amp; Delivery</h2>

      <h3>3.1. Stages of Labor</h3>
      <ol>
        <li><strong>Stage 1:</strong> Onset of true labor → Full cervical dilation (10 cm).
          <ul>
            <li>Latent Phase: Slow cervical dilation up to ~6 cm; can last ~20 hr in nullips, ~14 hr in multips.</li>
            <li>Active Phase: More rapid dilation from ~6 cm to 10 cm; ~1.2 cm/hr in nullips, 1.5 cm/hr in multips (traditional estimates).</li>
          </ul>
        </li>
        <li><strong>Stage 2:</strong> Full dilation → Delivery of fetus.
          <ul>
            <li>~2 hr in nullips (3 hr with epidural), ~1 hr in multips (2 hr with epidural).</li>
          </ul>
        </li>
        <li><strong>Stage 3:</strong> Delivery of fetus → Delivery of placenta.
          <ul>
            <li>Usually &lt;30 minutes. Check placenta for completeness.</li>
          </ul>
        </li>
      </ol>

      <h3>3.2. Labor Analgesia &amp; Pain Management</h3>
      <ul>
        <li><strong>Epidural Analgesia</strong>:
          <ul>
            <li>Most common; can cause hypotension, possible prolongation of the second stage.</li>
          </ul>
        </li>
        <li><strong>IV Opioids</strong>:
          <ul>
            <li>Used earlier in labor, watch for neonatal respiratory depression if near delivery.</li>
          </ul>
        </li>
        <li><strong>Non-Pharmacologic</strong>:
          <ul>
            <li>Continuous labor support (doula), breathing techniques, hydrotherapy, massage.</li>
          </ul>
        </li>
      </ul>

      <h3>3.3. Normal vs. Abnormal Labor Progression</h3>
      <ul>
        <li><strong>Friedman’s Curve vs. Modern Curves</strong>:
          <ul>
            <li>More time allowed before diagnosing arrest disorders.</li>
          </ul>
        </li>
        <li><strong>Arrest of Dilation</strong>: No cervical change despite adequate contractions for ≥2 hours in active phase.</li>
        <li><strong>Arrest of Descent</strong>: No descent of presenting part for ≥1 hour (nullips) or ≥30 min (multips) in second stage.</li>
        <li><strong>Three P’s</strong>: Power (contractions), Passenger (fetus size/presentation), Passage (pelvic anatomy).</li>
      </ul>

      <h3>3.4. Operative Delivery</h3>
      <ul>
        <li><strong>Vacuum Extraction / Forceps</strong>:
          <ul>
            <li>Indications: Prolonged second stage, suspicion of fetal compromise, need to shorten second stage for maternal benefit.</li>
            <li>Risks: Maternal lacerations, fetal scalp/cephalohematoma, intracranial hemorrhage (rare).</li>
          </ul>
        </li>
        <li><strong>Cesarean Delivery</strong>:
          <ul>
            <li>Indications: Failure to progress, non-reassuring fetal status, malpresentation, placenta previa, etc.</li>
            <li>Complications: Infection, hemorrhage, anesthesia risks, future placenta accreta.</li>
          </ul>
        </li>
      </ul>

      <h3>3.5. Fetal Monitoring &amp; Interpretation</h3>
      <ul>
        <li><strong>External vs. Internal</strong>: External uses Doppler for FHR, tocodynamometer for contractions; internal uses fetal scalp electrode + IUPC.</li>
        <li><strong>Baseline Fetal Heart Rate</strong>: 110–160 bpm.</li>
        <li><strong>Variability</strong>: Absent, minimal (&lt;5 bpm), moderate (6–25 bpm), marked (&gt;25 bpm). Moderate is reassuring.</li>
        <li><strong>Accelerations</strong>: Generally reassuring.</li>
        <li><strong>Decelerations</strong>:
          <ul>
            <li>Early: Mirror contractions; head compression → benign.</li>
            <li>Variable: Abrupt drops; cord compression.</li>
            <li>Late: Occur after peak of contraction; uteroplacental insufficiency → worrisome.</li>
          </ul>
        </li>
        <li><strong>Category I, II, III</strong>:
          <ul>
            <li>Category I: Normal, reassuring.</li>
            <li>Category II: Indeterminate, requires interventions/monitoring.</li>
            <li>Category III: Abnormal, indicates fetal distress → immediate action, possibly emergent delivery.</li>
          </ul>
        </li>
      </ul>
    </section>

    <!-- 4. Postpartum Care & Complications -->
    <section>
      <h2>4. Postpartum Care &amp; Complications</h2>

      <h3>4.1. Immediate Postpartum Period</h3>
      <ul>
        <li><strong>Uterine Involution</strong>: Uterus descends ~1 cm/day; by ~2 weeks postpartum, no longer palpable abdominally.</li>
        <li><strong>Lochia</strong>: Vaginal discharge postpartum.
          <ul>
            <li>Lochia rubra (red/bloody, ~3–4 days).</li>
            <li>Lochia serosa (pink/brown, up to ~10 days).</li>
            <li>Lochia alba (yellow/white, weeks).</li>
          </ul>
        </li>
      </ul>

      <h3>4.2. Postpartum Hemorrhage (PPH)</h3>
      <ul>
        <li><strong>Definition</strong>: 
          <ul>
            <li>≥500 mL after vaginal delivery,</li>
            <li>≥1000 mL after cesarean, or</li>
            <li>Any blood loss causing hemodynamic instability.</li>
          </ul>
        </li>
        <li><strong>Causes (Four T’s)</strong>:
          <ul>
            <li>Tone: Uterine atony (most common).</li>
            <li>Tissue: Retained placental tissue.</li>
            <li>Trauma: Lacerations, uterine rupture, hematomas.</li>
            <li>Thrombin: Coagulopathies (DIC, von Willebrand disease).</li>
          </ul>
        </li>
        <li><strong>Management</strong>:
          <ul>
            <li>Uterine massage, uterotonics (oxytocin, methylergonovine, carboprost, misoprostol).</li>
            <li>Identify and repair lacerations; remove retained tissue.</li>
            <li>Correct coagulopathy if present.</li>
          </ul>
        </li>
      </ul>

      <h3>4.3. Postpartum Infections</h3>
      <ul>
        <li><strong>Endometritis</strong>:
          <ul>
            <li>Infection of the decidua (uterine lining), more common after cesarean.</li>
            <li>Presentation: Fever, uterine tenderness, foul-smelling lochia.</li>
            <li>Management: Broad-spectrum antibiotics (clindamycin + gentamicin).</li>
          </ul>
        </li>
        <li><strong>Mastitis</strong>:
          <ul>
            <li>Typically due to Staphylococcus aureus in lactating women.</li>
            <li>Symptoms: Unilateral breast tenderness, erythema, warmth, fever.</li>
            <li>Management: Antibiotics (dicloxacillin, cephalexin), encourage continued breastfeeding or pumping.</li>
          </ul>
        </li>
        <li><strong>Wound Infections</strong>: At episiotomy or cesarean incision site → localized erythema, tenderness, possible drainage.</li>
      </ul>

      <h3>4.4. Postpartum Mood Disorders</h3>
      <ul>
        <li><strong>Baby Blues</strong>: Mild depressive symptoms, resolves by ~2 weeks.</li>
        <li><strong>Postpartum Depression</strong>: More severe, lasting &gt;2 weeks, may include anhedonia, guilt, possible thoughts of harm.</li>
        <li><strong>Postpartum Psychosis</strong>: Rare, severe; hallucinations, delusions. Medical emergency.</li>
      </ul>

      <h3>4.5. Lactation &amp; Breastfeeding</h3>
      <ul>
        <li><strong>Stages</strong>:
          <ul>
            <li>Colostrum first few days: High in antibodies.</li>
            <li>Mature milk by ~2 weeks postpartum.</li>
          </ul>
        </li>
        <li><strong>Benefits</strong>: Decreased infant infections, maternal weight loss, reduced risk of certain cancers.</li>
        <li><strong>Guidance</strong>: Breastfeed on demand (~8–12 times/day initially), ensure proper latch technique.</li>
      </ul>
    </section>

    <!-- 5. Contraception & Family Planning -->
    <section>
      <h2>5. Contraception &amp; Family Planning</h2>

      <h3>5.1. Hormonal Contraceptives</h3>
      <h4>5.1.1. Combined Oral Contraceptive Pills (COCs)</h4>
      <ul>
        <li>Estrogen + Progestin; suppress FSH/LH → prevent ovulation.</li>
        <li>Benefits: Regulate menses, decrease dysmenorrhea, reduce ovarian/endometrial cancer risk, improve acne.</li>
        <li>Risks: Thromboembolism, slight ↑ risk of breast cancer (controversial).</li>
        <li>Contraindications: Smoker ≥35 (≥15 cigarettes/day), history of thrombotic events, migraine with aura, breast cancer.</li>
      </ul>

      <h4>5.1.2. Progestin-Only Pills (POP, “Mini-Pill”)</h4>
      <ul>
        <li>Indicated for breastfeeding women or those with contraindications to estrogen.</li>
        <li>Thickens cervical mucus, partial ovulation suppression.</li>
        <li>Must be taken at the same time daily; short missed-dose window.</li>
      </ul>

      <h4>5.1.3. Depot Medroxyprogesterone (Depo-Provera)</h4>
      <ul>
        <li>Injection every 3 months.</li>
        <li>Side effects: Weight gain, irregular bleeding, possible bone density loss, delayed return to fertility.</li>
      </ul>

      <h4>5.1.4. Implant (Nexplanon)</h4>
      <ul>
        <li>Single-rod progestin implant in the upper arm, effective up to 3 years.</li>
        <li>Side effects: Irregular bleeding, possible headache, breast tenderness.</li>
      </ul>

      <h3>5.2. Intrauterine Devices (IUDs)</h3>
      <h4>5.2.1. Copper IUD (ParaGard)</h4>
      <ul>
        <li>Local inflammatory reaction toxic to sperm/ova.</li>
        <li>Duration: Up to 10+ years.</li>
        <li>Side Effects: Heavier, longer periods, dysmenorrhea.</li>
      </ul>

      <h4>5.2.2. Levonorgestrel IUD (Mirena, Skyla, Kyleena, Liletta)</h4>
      <ul>
        <li>Local progestin → thickens cervical mucus, thins endometrium, partial ovulation suppression.</li>
        <li>Duration: 3–5+ years depending on brand.</li>
        <li>Benefits: Lighter periods, possible amenorrhea, good for dysmenorrhea.</li>
      </ul>

      <h4>5.2.3. Contraindications to IUDs</h4>
      <ul>
        <li>Active pelvic infection (PID),</li>
        <li>Uterine anomalies/fibroids distorting the cavity,</li>
        <li>Unexplained uterine bleeding (investigate first).</li>
      </ul>

      <h3>5.3. Barrier Methods &amp; Sterilization</h3>
      <ul>
        <li><strong>Condoms</strong> (male/female): Only method also offering some STI protection.</li>
        <li><strong>Diaphragm</strong>: Fitted by provider, used with spermicide, must remain 6+ hours post-coitus.</li>
        <li><strong>Sterilization</strong>:
          <ul>
            <li>Female: Tubal ligation or salpingectomy.</li>
            <li>Male: Vasectomy (verify azoospermia before relying on it).</li>
          </ul>
        </li>
      </ul>

      <h3>5.4. Emergency Contraception (EC)</h3>
      <ul>
        <li>Levonorgestrel (Plan B) within 72 hours (OTC in many regions).</li>
        <li>Ulipristal acetate (Ella) up to 120 hours (prescription).</li>
        <li>Copper IUD (most effective) within 5 days; also provides ongoing contraception.</li>
      </ul>
    </section>

    <!-- 6. Gynecology: General Topics -->
    <section>
      <h2>6. Gynecology: General Topics</h2>

      <h3>6.1. Menstrual Disorders</h3>
      <h4>6.1.1. Abnormal Uterine Bleeding (AUB)</h4>
      <ul>
        <li><strong>PALM-COEIN classification</strong>: Polyp, Adenomyosis, Leiomyoma, Malignancy, Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified.</li>
        <li><strong>Workup</strong>:
          <ul>
            <li>Pregnancy test, pelvic ultrasound, labs (CBC, TSH, prolactin), endometrial sampling if ≥45 or risk factors.</li>
          </ul>
        </li>
        <li><strong>Management</strong>:
          <ul>
            <li>Hormonal therapy (COCs, progestin-only, high-dose estrogen for acute bleeding).</li>
            <li>Tranexamic acid or NSAIDs for heavy menses.</li>
            <li>Surgical options: Endometrial ablation, myomectomy, hysterectomy if definitive.</li>
          </ul>
        </li>
      </ul>

      <h4>6.1.2. Dysmenorrhea</h4>
      <ul>
        <li>Primary: Painful menses without pelvic pathology (prostaglandin-mediated).</li>
        <li>Secondary: Due to underlying pathology (endometriosis, fibroids, adenomyosis).</li>
        <li>Management: NSAIDs, hormonal contraceptives, address underlying cause.</li>
      </ul>

      <h4>6.1.3. Amenorrhea</h4>
      <ul>
        <li>Primary: No menarche by 15 (with secondary sex characteristics) or 13 (without).</li>
        <li>Secondary: No menses for 3 months (regular cycles) or 6 months (irregular cycles).</li>
        <li>Workup: β-hCG to rule out pregnancy, TSH, prolactin, FSH/LH, check anatomic causes.</li>
      </ul>

      <h3>6.2. Menopause &amp; Perimenopause</h3>
      <ul>
        <li>Definition: 12 consecutive months of amenorrhea, average age ~51.</li>
        <li>Symptoms: Vasomotor (hot flashes, night sweats), mood changes, vaginal atrophy, osteoporosis risk.</li>
        <li>HRT: Estrogen ± progesterone if uterus intact; watch for thromboembolism, breast cancer risk.</li>
        <li>Alternatives: SSRIs (paroxetine), gabapentin, clonidine for hot flashes, topical vaginal estrogens for atrophy.</li>
      </ul>

      <h3>6.3. Pelvic Organ Prolapse</h3>
      <ul>
        <li><strong>Types</strong>:
          <ul>
            <li>Cystocele (bladder → anterior vagina).</li>
            <li>Rectocele (rectum → posterior vagina).</li>
            <li>Uterine prolapse (uterus descends into vaginal canal).</li>
          </ul>
        </li>
        <li><strong>Risk Factors</strong>: Multiparity, advanced age, obesity, chronic cough/constipation.</li>
        <li><strong>Management</strong>:
          <ul>
            <li>Pelvic floor exercises (Kegels), pessaries, surgical repair if severe.</li>
          </ul>
        </li>
      </ul>

      <h3>6.4. Urinary Incontinence</h3>
      <ul>
        <li>Stress: Leakage with coughing, sneezing (urethral hypermobility).</li>
        <li>Urge: Overactive bladder, detrusor overactivity → sudden urge to void.</li>
        <li>Overflow: Chronic retention, incomplete emptying.</li>
        <li>Management:
          <ul>
            <li>Stress: Kegels, pessaries, mid-urethral sling.</li>
            <li>Urge: Bladder training, anticholinergics (oxybutynin), β3 agonists (mirabegron).</li>
          </ul>
        </li>
      </ul>

      <h3>6.5. Pelvic Pain &amp; Dysmenorrhea</h3>
      <p>Evaluate for endometriosis, adenomyosis, PID, GI or urinary causes. Primary dysmenorrhea often treated with NSAIDs, hormonal contraceptives.</p>

      <h3>6.6. Endometriosis</h3>
      <ul>
        <li>Ectopic endometrial tissue (ovaries, peritoneum).</li>
        <li>Symptoms: Dysmenorrhea, dyspareunia, chronic pelvic pain, infertility.</li>
        <li>Diagnosis: Laparoscopy is gold standard.</li>
        <li>Management: NSAIDs, hormonal suppression, surgical ablation/excision if severe.</li>
      </ul>

      <h3>6.7. Uterine Leiomyomas (Fibroids)</h3>
      <ul>
        <li>Benign smooth muscle tumors of the uterus, estrogen-responsive.</li>
        <li>Symptoms: Heavy menstrual bleeding, pelvic pressure, infertility (depending on location).</li>
        <li>Diagnosis: Pelvic exam (irregularly enlarged uterus), ultrasound.</li>
        <li>Management: GnRH agonists, surgical (myomectomy if fertility desired, hysterectomy if definitive).</li>
      </ul>

      <h3>6.8. Adenomyosis</h3>
      <ul>
        <li>Endometrial glands/stroma within myometrium.</li>
        <li>Symptoms: Dysmenorrhea, menorrhagia, uniformly “boggy” enlarged uterus.</li>
        <li>Diagnosis: MRI/TVUS can assist, definitive via histology (post-hysterectomy).</li>
        <li>Management: NSAIDs, hormonal therapy, definitive = hysterectomy.</li>
      </ul>
    </section>

    <!-- 7. Gynecologic Oncology -->
    <section>
      <h2>7. Gynecologic Oncology</h2>

      <h3>7.1. Cervical Cancer</h3>
      <ul>
        <li>Etiology: HPV infection (types 16, 18, 31, 33).</li>
        <li>Screening: Pap smear at 21; co-testing (Pap + HPV) at 30–65 if desired.</li>
        <li>Abnormal results: ASC-US → reflex HPV or repeat Pap; LSIL/HSIL → colposcopy/biopsy.</li>
        <li>HPV vaccine recommended at ages 11–12, up to 45 in some cases.</li>
        <li>Management: Pre-invasive (LEEP, conization); invasive (hysterectomy or chemo/radiation depending on stage).</li>
      </ul>

      <h3>7.2. Endometrial (Uterine) Cancer</h3>
      <ul>
        <li>Risk Factors: Obesity, unopposed estrogen, PCOS, Lynch syndrome, nulliparity.</li>
        <li>Presentation: Postmenopausal bleeding.</li>
        <li>Diagnosis: Endometrial biopsy is gold standard, TVUS for endometrial stripe measurement.</li>
        <li>Management: TAH-BSO ± lymph node sampling, possible radiation/chemo depending on stage.</li>
      </ul>

      <h3>7.3. Ovarian Cancer</h3>
      <ul>
        <li>Risk Factors: Family history, BRCA1/2, Lynch, increased ovulatory cycles.</li>
        <li>Symptoms: Bloating, abdominal pain, early satiety, urinary frequency.</li>
        <li>Diagnosis: Pelvic ultrasound, CA-125 marker, surgical exploration.</li>
        <li>Management: Debulking surgery + platinum-based chemo, monitor CA-125 for recurrence.</li>
      </ul>

      <h3>7.4. Vulvar &amp; Vaginal Cancers</h3>
      <ul>
        <li><strong>Vulvar Cancer</strong>: HPV-related or lichen sclerosus; pruritus, ulcer/mass.</li>
        <li><strong>Vaginal Cancer</strong>: Rare, often metastatic from cervix or endometrium; bleeding, mass.</li>
        <li>Diagnosis by biopsy, treatment with surgery ± radiation.</li>
      </ul>

      <h3>7.5. Gestational Trophoblastic Disease (GTD)</h3>
      <ul>
        <li><strong>Hydatidiform Mole</strong> (complete or partial), Invasive Mole, Choriocarcinoma.</li>
        <li><strong>Complete Mole</strong>: 46XX (all paternal), no fetus, very high β-hCG, “snowstorm” ultrasound.</li>
        <li><strong>Partial Mole</strong>: Triploid (69XXY), some fetal tissue, lower malignant potential.</li>
        <li><strong>Management</strong>:
          <ul>
            <li>D&amp;C, then weekly β-hCG checks until undetectable.</li>
            <li>If β-hCG rises or plateaus → suspect persistent GTN → methotrexate chemo.</li>
          </ul>
        </li>
      </ul>
    </section>

    <!-- 8. Breast Disorders -->
    <section>
      <h2>8. Breast Disorders</h2>

      <h3>8.1. Benign Breast Conditions</h3>
      <ul>
        <li><strong>Fibrocystic Changes</strong>:
          <ul>
            <li>Cyclical breast pain, lumps vary with menstrual cycle.</li>
            <li>Ultrasound/mammogram for evaluation, biopsy if suspicious.</li>
          </ul>
        </li>
        <li><strong>Fibroadenoma</strong>:
          <ul>
            <li>Solid, well-defined, mobile mass, common in younger women.</li>
            <li>Usually painless. Confirm with imaging ± core biopsy.</li>
          </ul>
        </li>
      </ul>

      <h3>8.2. Malignant Breast Disease</h3>
      <ul>
        <li><strong>Risk Factors</strong>: Age, BRCA1/2, early menarche, late menopause, nulliparity, HRT, alcohol.</li>
        <li><strong>Screening</strong>: Mammograms starting at 40 or 50 (guideline-dependent), MRI in high-risk cases.</li>
        <li><strong>Common Types</strong>: Invasive ductal carcinoma (most common), invasive lobular carcinoma.</li>
        <li><strong>Management</strong>:
          <ul>
            <li>Surgery (lumpectomy + radiation or mastectomy).</li>
            <li>Adjuvant chemo/hormonal therapy (e.g., tamoxifen, aromatase inhibitors).</li>
            <li>Targeted therapy (HER2+ → trastuzumab).</li>
          </ul>
        </li>
      </ul>

      <h3>8.3. Mastitis &amp; Breast Abscess</h3>
      <ul>
        <li><strong>Mastitis</strong>:
          <ul>
            <li>Infection (S. aureus) in lactating women; keep breastfeeding, antibiotics (dicloxacillin, cephalexin).</li>
          </ul>
        </li>
        <li><strong>Breast Abscess</strong>: If fluctuant mass, may require ultrasound-guided aspiration or I&amp;D.</li>
      </ul>
    </section>

    <!-- 9. Reproductive Endocrinology & Infertility -->
    <section>
      <h2>9. Reproductive Endocrinology &amp; Infertility</h2>

      <h3>9.1. Definitions &amp; Workup</h3>
      <ul>
        <li>Infertility: No conception after 12 months of unprotected intercourse if &lt;35 yrs, or 6 months if ≥35 yrs.</li>
        <li>Initial Workup:
          <ul>
            <li>Ovulatory function: mid-luteal progesterone, LH surge kits.</li>
            <li>Semen analysis.</li>
            <li>Hysterosalpingography (HSG) to check tubal patency.</li>
            <li>Labs: TSH, prolactin, FSH/LH, estradiol, AMH.</li>
          </ul>
        </li>
      </ul>

      <h3>9.2. Common Causes</h3>
      <ul>
        <li>PCOS (insulin resistance, anovulation).</li>
        <li>Hypothalamic Amenorrhea (low GnRH due to stress, low weight, excessive exercise).</li>
        <li>Hyperprolactinemia (inhibits GnRH → anovulation).</li>
        <li>Tubal Disease (PID, endometriosis).</li>
        <li>Male Factors (low count/motility).</li>
      </ul>

      <h3>9.3. Treatments</h3>
      <ul>
        <li><strong>Ovulation Induction</strong>: Clomiphene citrate, letrozole.</li>
        <li><strong>ART</strong>: Intrauterine insemination (IUI), IVF, ICSI for severe male factor.</li>
        <li>Referral to fertility specialist for advanced interventions.</li>
      </ul>
    </section>

    <!-- 10. Sexually Transmitted Infections (STIs) & Other Gynecologic Infections -->
    <section>
      <h2>10. Sexually Transmitted Infections (STIs) &amp; Other Gynecologic Infections</h2>

      <h3>10.1. Common STIs &amp; Treatment</h3>
      <ul>
        <li><strong>Chlamydia</strong>: Azithromycin 1 g PO once or Doxycycline 100 mg PO bid x 7 days.</li>
        <li><strong>Gonorrhea</strong>: Ceftriaxone 500 mg IM once (if &lt;150 kg) + Doxycycline if chlamydia not ruled out.</li>
        <li><strong>Trichomoniasis</strong>: Metronidazole 2 g PO once.</li>
        <li><strong>Bacterial Vaginosis</strong>: Metronidazole 2 g PO once or 500 mg PO bid x 7 days.</li>
        <li><strong>Syphilis</strong>: Penicillin G benzathine IM; dose/stage-dependent.</li>
        <li><strong>Herpes (HSV)</strong>: Acyclovir or valacyclovir (episodic or suppressive).</li>
        <li><strong>HPV</strong>: Genital warts (types 6, 11) → cryotherapy or surgical removal; vaccination for prevention.</li>
      </ul>

      <h3>10.2. Pelvic Inflammatory Disease (PID)</h3>
      <ul>
        <li>Infection of upper genital tract (endometritis, salpingitis, TOA).</li>
        <li>Pathogens: N. gonorrhoeae, C. trachomatis.</li>
        <li>Symptoms: Cervical motion tenderness (Chandelier sign), pelvic pain, fever.</li>
        <li>Management: Ceftriaxone IM + doxycycline ± metronidazole outpatient; IV regimen if severe.</li>
      </ul>

      <h3>10.3. Screening in Pregnancy</h3>
      <ul>
        <li>All pregnant women: Syphilis, HIV, Hep B, retest high-risk in 3rd trimester.</li>
        <li>Gonorrhea/Chlamydia: Test high-risk populations.</li>
        <li>Herpes: Not universal, but important to manage lesions near delivery.</li>
      </ul>
    </section>

    <!-- 11. Ectopic Pregnancy -->
    <section>
      <h2>11. Ectopic Pregnancy</h2>

      <h3>11.1. Risk Factors</h3>
      <ul>
        <li>Prior ectopic, PID, tubal surgery, endometriosis, IUD in situ, IVF.</li>
      </ul>

      <h3>11.2. Clinical Presentation &amp; Diagnosis</h3>
      <ul>
        <li>Unilateral pelvic/abdominal pain, vaginal bleeding, possible referred shoulder pain if rupture.</li>
        <li>Physical exam: Adnexal tenderness/mass, hemodynamic instability if ruptured.</li>
        <li>Labs: Serial β-hCG, abnormal rise (&lt;53% in 48 hrs). Transvaginal ultrasound essential.</li>
      </ul>

      <h3>11.3. Management</h3>
      <ul>
        <li><strong>Medical</strong>: Methotrexate if stable, unruptured, β-hCG &lt;5000, no fetal heartbeat, reliable follow-up.</li>
        <li><strong>Surgical</strong>: Salpingostomy or salpingectomy if ruptured or contraindications to methotrexate.</li>
        <li><strong>Follow-up</strong>: β-hCG must decline to undetectable to confirm resolution.</li>
      </ul>

    </section>

    <section>
      <h2>Final Tips for PANCE Preparation</h2>
      <ol>
        <li><strong>Stay Updated on Guidelines:</strong> Always check latest recommendations from ACOG, USPSTF, CDC.</li>
        <li><strong>Master Common Scenarios:</strong> GDM, preeclampsia, postpartum hemorrhage, abnormal uterine bleeding, STIs, cervical cancer screening.</li>
        <li><strong>Pharmacologic Details:</strong> Mechanisms, contraindications, side effects of key drugs (e.g., contraceptives, antibiotics).</li>
        <li><strong>Differentiate Normal vs. Abnormal:</strong> Normal pregnancy physiology and labor progress vs. pathological findings.</li>
        <li><strong>Practice Questions:</strong> Use clinical vignettes to build confidence in diagnosis and management steps.</li>
      </ol>
    </section>

  </main>

  <footer class="site-footer">
    <p>&copy; <span id="currentYear"></span> M & M Consulting. All rights reserved. Xamtac is the best.</p>
  </footer>

  <script>
    "use strict";

    // Dynamically update the year in the footer
    document.getElementById('currentYear').textContent = new Date().getFullYear();

    // Toggle navigation for mobile
    const navToggle = document.getElementById("nav-toggle");
    const navLinks = document.getElementById("nav-links");

    if (navToggle) {
      navToggle.addEventListener("click", () => {
        const expanded = navToggle.getAttribute('aria-expanded') === 'true';
        navToggle.setAttribute('aria-expanded', String(!expanded));
        navLinks.classList.toggle("open");
      });
    }
  </script>
</body>
</html>